- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules | ||
| Fr | UK consumers seeking advice from pharmacists during pandemic, research finds | ||
| Fr | Novavax begins phase III coronavirus vaccine trial in the UK | ||
| Fr | Accord Healthcare launches Herceptin biosimilar in the UK | ||
| Do | Oncimmune partners with Genentech to profile samples from rheumatology trials | ||
| Do | Verona Pharma launches late-stage COPD trial programme | ||
| Do | FDA and EMA accept regulatory submissions for UCB's bimekizumab | ||
| Do | NHS COVID-19 app launches in England and Wales | ||
| Mi | Digital tech has health benefits for dementia patients, project finds | ||
| Mi | Owlstone Medical's breath biopsy test improves detection of liver disease | ||
| Mi | Vertex, CRISPR Therapeutics' sickle cell gene therapy wins PRIME designation | ||
| Mi | Sanofi, GSK ink deal with EU for 300 million COVID-19 vaccine doses | ||
| Di | Bristol Myers Squibb's Opdivo shows benefit in oesophageal cancers | ||
| Di | Roche acquires Irish biotech firm Inflazome | ||
| Di | GSK's Zejula and AstraZeneca's Lynparza leap toward broader EU approval | ||
| Di | UK's chief medical officers upgrade coronavirus alert level | ||
| Mo | Keytruda/Lenvima combo shows promise in hard-to-treat cancers | ||
| Mo | University of Edinburgh spinout Cellinta will develop gene therapies for cancer | ||
| Mo | Lynparza scores long-term benefit data in BRCA-mutated ovarian cancer | ||
| Mo | CHMP backs seven new meds in September meeting | ||
| 18.09. | BMS' Opdivo wins new NICE lung cancer backing | ||
| 18.09. | Bayer's Vitrakvi shows long-term efficacy in TRK fusion-positive cancers | ||
| 18.09. | Access to coronavirus tests should be 'top priority', says NHS Confederation director | ||
| 18.09. | NICE u-turn sees Akcea's Waylivra win NHS funding | ||
| 17.09. | IVD industry must be supported in COVID-19 recovery strategy, says BIVDA |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
